We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
-20.8%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$279M
AUM Growth
+$40.4M
Cap. Flow
+$105M
Cap. Flow %
37.71%
Top 10 Hldgs %
65.76%
Holding
38
New
13
Increased
10
Reduced
2
Closed
5

Top Buys

Rank Stock Value
1
BLUE
bluebird bio
BLUE
+$18.6M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$12.9M
3
ADMS
Adamas Pharmaceuticals
ADMS
+$11.3M
4
TTPH
Tetraphase Pharmaceuticals, Inc.
TTPH
+$8.56M
5
CMRX
Chimerix, Inc.
CMRX
+$8.49M

Top Sells

Rank Stock Value
1
TTHI
TRANSITION THERAPEUTICS INC (CANADA)
TTHI
+$1.65M
2
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
+$765K
3
LSTA icon
Lisata Therapeutics
LSTA
+$353K

Sector Composition

Rank Sector Weight
1 Healthcare 68.66%
2 Technology 3.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADMS
1
DELISTED
Adamas Pharmaceuticals
ADMS
$30.5M 10.94%
2,109,099
+671,764
+47% +$11.3M
FPRX
2
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$23.4M 8.38%
575,000
+5,342
+0.9% +$184K
VNDA icon
3
Vanda Pharmaceuticals
VNDA
$307M
$22.8M 8.19%
2,731,210
+631,109
+30% +$5.18M
ZGNX
4
DELISTED
Zogenix, Inc.
ZGNX
$19.3M 6.92%
2,085,959
+671,032
+47% +$6.72M
TTPH
5
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$16.9M 6.07%
182,660
+85,660
+88% +$8.56M
BLUE
6
DELISTED
bluebird bio
BLUE
$16.7M 6%
+30,350
New +$18.6M
EXEL icon
7
Exelixis
EXEL
$13.3B
$15.6M 5.59%
3,896,113
+1,863,619
+92% +$7.89M
NBIX icon
8
Neurocrine Biosciences
NBIX
$16.8B
$12.9M 4.62%
+325,300
New +$12.9M
ICPT
9
PUT
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$12.8M 4.61%
+100,000
New +$11.8M
VCEL icon
10
Vericel Corp
VCEL
$2.35B
$12.4M 4.44%
2,110,738
+24,710
+1% +$69.3K
CNXR
11
DELISTED
Connecture, Inc.
CNXR
$10.6M 3.79%
4,127,232
– –
ARCT icon
12
Arcturus Therapeutics
ARCT
$164M
$7.66M 2.75%
288,595
+1,078
+0.4% +$36.5K
AUPH icon
13
Aurinia Pharmaceuticals
AUPH
$1.91B
$7.19M 2.58%
2,457,144
– –
XNCR icon
14
Xencor
XNCR
$1.5B
$7.09M 2.55%
+528,692
New +$6.26M
ADVM
15
DELISTED
Adverum Biotechnologies
ADVM
$6.7M 2.4%
+129,542
New +$7.23M
CMRX
16
DELISTED
Chimerix, Inc.
CMRX
$6.64M 2.38%
+1,300,000
New +$8.49M
RPTP
17
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
$6.19M 2.22%
1,346,344
+63,817
+5% +$257K
SGYP
18
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$6M 2.15%
2,175,000
+628,112
+41% +$2.27M
OCRX
19
DELISTED
Ocera Therapeutics, Inc.
OCRX
$5.77M 2.07%
1,963,777
– –
PRTK
20
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$4.63M 1.66%
305,459
-50,000
-14% -$765K
APYX icon
21
Apyx Medical
APYX
$173M
$4.48M 1.61%
2,680,000
– –
VIRX
22
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$4.46M 1.6%
39,286
– –
ARDM
23
DELISTED
Aradigm Corp Common Stock
ARDM
$4.45M 1.6%
1,002,962
– –
SRPT icon
24
CALL
Sarepta Therapeutics
SRPT
$1.57B
$2.93M 1.05%
+150,000
New +$2.62M
ACAD icon
25
Acadia Pharmaceuticals
ACAD
$4.43B
$2.8M 1%
+100,000
New +$2.18M
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q1 2016 Portfolio in Review

As of Q1 2016, Great Point Partners held 38 positions worth $279M, up 17% from $238M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Great Point Partners deployed $105M of net new capital in Q1 2016, opening 13 new positions and adding to 10 existing holdings. Its largest new stake was bluebird bio: 30,350 shares worth $16.7M.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, up from 58% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Paratek Pharmaceuticals, Inc., an estimated $765K trimmed.

  • Great Point Partners's largest Q1 2016 buy was bluebird bio: 30,350 shares worth $16.7M.
  • Great Point Partners added most to Adamas Pharmaceuticals in Q1 2016, an estimated $11.3M increase.
  • Great Point Partners's biggest Q1 2016 reduction was Paratek Pharmaceuticals, Inc., cutting an estimated $765K.
  • Great Point Partners fully exited TRANSITION THERAPEUTICS INC (CANADA) in Q1 2016, selling an estimated $1.65M.
  • Great Point Partners's ten largest holdings make up 66% of its $279M portfolio in Q1 2016.
  • Great Point Partners opened 13 new positions and closed 5 in Q1 2016.
  • Great Point Partners's portfolio value rose 17% quarter-over-quarter to $279M.

Based on Great Point Partners's 13F filing for Q1 2016, filed 16 May 2016.